PRO-CTCAE™:
PATIENT-REPORTED OUTCOMES
VERSION OF CTCAE

Lori Minasian, MD
Deputy Director, Division of Cancer Prevention, NCI
Disclosures

• I work for the USA Federal Government

• I have no financial conflicts to disclose

• Presenting on behalf of the NCI PRO-CTCAE Scientific Leadership Team
Outline of Talk

• Psychometric development for PRO-CTCAE™

• Describe initial principles for use

• Identify differences
  • between HRQOL tools and toxicity reporting
What is PRO-CTCAE™?

• PRO-CTCAE is designed for patient reporting of symptomatic adverse events

• PRO-CTCAE is an item bank of questions
  • Derived from the CTCAE adverse event items
  • Complimentary to CTCAE (and to be used with)

• PRO-CTCAE is ONLY for descriptive reporting
  • Not ready for clinical and protocol specific decision-making based upon individual PRO-CTCAE scores
## PRO-CTCAE Measurement System

<table>
<thead>
<tr>
<th>1. Symptom Library</th>
<th>2. System for Survey Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 78 symptomatic adverse events drawn from CTCAE</td>
<td>• Web-based system to customize surveys and manage survey administration</td>
</tr>
<tr>
<td>• PRO-CTCAE questions evaluate symptom occurrence, frequency, severity, and interference</td>
<td>• Patient responds to surveys using web, tablet or interactive voice response (IVRS) telephone system</td>
</tr>
<tr>
<td></td>
<td>• Conditional branching (skip patterns)</td>
</tr>
<tr>
<td></td>
<td>• Write-ins with automatic mapping to standardized terminology</td>
</tr>
</tbody>
</table>

For more information, visit: [http://outcomes.cancer.gov/tools/pro-ctcae.html](http://outcomes.cancer.gov/tools/pro-ctcae.html)
- Psychometrically robust library of items
- Electronic system fits data collection smoothly into trials workflow and offers favorable user-experience
- Accommodate patients with limited English proficiency/digital literacy
- Supply meaningful data to improve understanding of symptomatic AEs

- Electronic system for survey mgmt
- Usability testing
- Implement telephone reporting (IVRS)
- Spanish Validation
- Feasibility, Acceptability & Cost

Funded by NCI contracts HHSN261200800043C, HHSN261201000063C, and HHSN261200800001E
PRO-CTCAE Content Validity

- 78 symptomatic AEs identified from ~800 CTCAE terms for patient self-reporting
  - Plain-language AE terms identified
- Each symptomatic AE has 1 to 3 items¹
  - Frequency, severity, interference w/ activities
- Content validity established during three interview rounds with semi-structured interview using structured and open-ended probes (N=127)²
  - 63/80 symptom terms generated no cognitive difficulties; 17 modified and re-tested without further difficulties

¹Basch et al., (2014). Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9). pii: dju244
²Hay et al. (2014). Cognitive interviewing of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to support content validity. Quality of Life Research, 23(1):257-269
<table>
<thead>
<tr>
<th><strong>Oral</strong></th>
<th><strong>Cardio/Circulatory</strong></th>
<th><strong>Neurological</strong></th>
<th><strong>Sleep/Wake</strong></th>
<th><strong>Sexual</strong></th>
<th><strong>Gynecologic/Urinary</strong></th>
<th><strong>Mood</strong></th>
<th><strong>Miscellaneous</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry mouth</td>
<td>Swelling</td>
<td>Numbness &amp; tingling</td>
<td>Insomnia</td>
<td>Achieve and maintain erection</td>
<td>Irregular periods/vaginal bleeding</td>
<td>Anxious</td>
<td>Breast swelling and tenderness</td>
</tr>
<tr>
<td>Difficulty swallowing</td>
<td>Heart palpitations</td>
<td>Dizziness</td>
<td>SI</td>
<td>Ejaculation</td>
<td>Missed expected menstrual period</td>
<td>FSI</td>
<td>Bruising</td>
</tr>
<tr>
<td>Mouth/throat sores</td>
<td>S</td>
<td>SI</td>
<td>Fatigue</td>
<td>Decreased libido</td>
<td>Vaginal discharge</td>
<td>Discouraged</td>
<td>Chills</td>
</tr>
<tr>
<td>Cracking at the corners of the mouth (cheilosis/cheilitis)</td>
<td>S</td>
<td>SI</td>
<td>FSI</td>
<td>Delayed orgasm</td>
<td>Vaginal dryness</td>
<td>Sad</td>
<td>Increased sweating</td>
</tr>
<tr>
<td>Voice quality changes</td>
<td>P</td>
<td>FSI</td>
<td>SI</td>
<td>Unable to have orgasm</td>
<td>Painful urination</td>
<td>FSI</td>
<td>Decreased sweating</td>
</tr>
<tr>
<td>Hoarseness</td>
<td>S</td>
<td>FSI</td>
<td>FI</td>
<td>Pain w/sexual intercourse</td>
<td>Urinary urgency</td>
<td>FSI</td>
<td>Hot flashes</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td><strong>Cutaneous</strong></td>
<td><strong>Visual/Perceptual</strong></td>
<td><strong>Attention/Memory</strong></td>
<td><strong>Pain</strong></td>
<td><strong>Dimensions</strong></td>
<td><strong>Respiratory</strong></td>
<td></td>
</tr>
<tr>
<td>Taste changes</td>
<td>Rash</td>
<td>Blurred vision</td>
<td>Concentration</td>
<td>General pain</td>
<td>F: Frequency</td>
<td>Shortness of breath</td>
<td>SI</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>Skin dryness</td>
<td>Flashing lights</td>
<td>SI</td>
<td>Headache</td>
<td>I: Interference</td>
<td>Cough</td>
<td>SI</td>
</tr>
<tr>
<td>Nausea</td>
<td>Acne</td>
<td>Visual floaters</td>
<td>SI</td>
<td>Muscle pain</td>
<td>S: Severity</td>
<td>Wheezing</td>
<td>S</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Hair loss</td>
<td>Watery eyes</td>
<td>SI</td>
<td>Joint pain</td>
<td>P: Presence/Absence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heartburn</td>
<td>Itching</td>
<td>Ringing in ears</td>
<td>S</td>
<td></td>
<td>Amount</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gas</td>
<td>Hives</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bloating</td>
<td>Hand-foot syndrome</td>
<td></td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hiccups</td>
<td>Nail loss</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>Nail ridging</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Nail discoloration</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Sensitivity to sunlight</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal incontinence</td>
<td>Bed/pressure sores</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>Radiation skin reaction</td>
<td></td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>Skin darkening</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>Stretch marks</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wheezing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dimensions:
- F: Frequency
- I: Interference
- S: Severity
- P: Presence/Absence/Amount
PRO-CTCAE Validity and Reliability

- Results demonstrate favorable validity, reliability, and responsiveness of PRO-CTCAE in a large, heterogeneous sample of patients undergoing cancer treatment (n=940)\(^1\)
  - Most PRO-CTCAE items (119/124) reached a statistically significant (\(p<0.05\)) and meaningful effect size on one or more validity criteria
  - Majority of the items tested (n=27 items) exhibited acceptable test-retest reliability
  - All tested items (n=27 items) were sensitive to differences between groups

Comparison of Recall Periods

- N=110 patients completed 27 PRO-CTCAE items (14 symptomatic A/Es)
  - Comparison of 28 daily ratings to 1-, 2-, 3-, and 4-week recalled ratings
  - 1-week recall corresponds well to daily reporting. Differences between daily and longer recall periods widen with 2, 3, and 4 week recall

<table>
<thead>
<tr>
<th>Recall Period</th>
<th>Effect Size of the Difference (compared to max. daily score within that period)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 day</td>
<td>-0.2</td>
</tr>
<tr>
<td>14 day</td>
<td>-0.31</td>
</tr>
<tr>
<td>21 day</td>
<td>-0.39</td>
</tr>
<tr>
<td>Past month</td>
<td>-0.40</td>
</tr>
</tbody>
</table>
Timeframe for Assessments

• Recall period is 7 days
  • Anticipate weekly reporting
  • Currently, data to demonstrate ~ 90% compliance for weekly reporting up to 20 weeks with reminders.
  • Baseline and off-study assessment are essential
  • Balance number of items asked and frequency of time for assessments with data quality

• If asking questions with an interval of longer than one week, the recall period remains the last 7 days
Mode Equivalence

- N=112 patients completed 28 PRO-CTCAE items (14 symptomatic AEs) by each of the three modes of administration at a single clinic visit

- Average time to complete an item:
  - Web: 11.1 seconds (SD = ±8.4)
  - Interactive Voice Response (IVRS): 16.3 seconds (SD = ±6.3)
  - Paper: 10.3 seconds (SD = ±5.8)

Between modes, item-level mean differences were very small, and the corresponding effect sizes were all less than 0.20

<table>
<thead>
<tr>
<th></th>
<th>Median ICC (Range)</th>
<th>Median (range) between-mode item-level mean difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web vs IVRS</td>
<td>0.78 (0.56 - 0.90)</td>
<td>-0.04 (-0.16 - 0.22)</td>
</tr>
<tr>
<td>Web vs paper</td>
<td>0.81 (0.61 - 0.96)</td>
<td>-0.02 (-0.11 - 0.14)</td>
</tr>
<tr>
<td>IVRS vs paper</td>
<td>0.78 (0.59 - 0.91)</td>
<td>0.02 (-0.07 - 0.19)</td>
</tr>
</tbody>
</table>

Technology May Improve Data Collection

- Electronic administration reduces the number of items that must be asked of patients
  - Conditional branching
  - Computer adaptive testing
- Technology has enabled data collection to be more efficient, customized, mobile, and responsive
  - Smart phone/hand-held devices/Interactive Voice Response (IVRS) for data collection
  - Customize time of day for assessment, text size on screen, and mode of administration
  - Reminders to patients and staff for missed surveys
  - Eliminate need for data entry
  - Mobile devices may improve engagement
Example from Actual Trial: Compliance over Time

Weekly reporting from home via Web or IVRS (patient choice), with central monitoring and backup human telephone calls

Supported by NCI contract HHSN261201000063C
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)

This site was designed to provide you with information about the PRO-CTCAE, a patient-reported outcome measurement system developed by the National Cancer Institute to capture symptomatic adverse events in patients on cancer clinical trials.

The site includes an overview of the methods used to develop this measurement system, and resources and references for further information.

- What Is PRO-CTCAE?
- How Do I Use PRO-CTCAE?
- Overview
- Instrument
- Permission to Use
- Build a Custom Form
- Development Team
- PRO-CTCAE Scientific Leadership at NCI
- Resources
- Frequently Asked Questions
Toxicity Reporting & PRO-CTCAE

• Toxicity Reporting
  • Clinician assesses adverse events and grade events
  • Action is taken based upon protocol specific instructions for the purpose of preventing or reducing harm
  • Events reviewed in real time and study design may be modified
  • Each event is reported and analyzed independently

• PRO-CTCAE
  • Patient answers separate questions about occurrence of event
  • If event occurs, answer questions about frequency, severity or interference
  • No protocol directed modifications based only on patient reports
  • Each event evaluated individually (No summary score)
CTCAE Use Within Clinical Trials

• Protocol parameters
  • Patient Eligibility
  • Dose Limiting Toxicity (DLT)
  • Maximum Tolerated Dose (MTD) determination
  • Dose Modification
• Recommended Phase 2 dose
• Reporting of both routine adverse events and serious adverse events (SAE)
• Monitor safety data and regulatory reporting
<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>CTCAE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucositis oral</td>
<td>1: Asymptomatic or mild symptoms; intervention not indicated</td>
</tr>
<tr>
<td></td>
<td>2: Moderate pain; not interfering with oral intake; modified diet indicated</td>
</tr>
<tr>
<td></td>
<td>3: Severe pain; interfering with oral intake</td>
</tr>
<tr>
<td></td>
<td>4: Life-threatening consequences; urgent intervention indicated</td>
</tr>
<tr>
<td></td>
<td>5: -</td>
</tr>
</tbody>
</table>

**CTCAE vs. PRO-CTCAE™ Item Structures**

**CTCAE**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Asymptomatic or mild symptoms; intervention not indicated</td>
</tr>
<tr>
<td>2</td>
<td>Moderate pain; not interfering with oral intake; modified diet indicated</td>
</tr>
<tr>
<td>3</td>
<td>Severe pain; interfering with oral intake</td>
</tr>
<tr>
<td>4</td>
<td>Life-threatening consequences; urgent intervention indicated</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
</tr>
</tbody>
</table>

**PRO-CTCAE**

Please think back over the past 7 days:

- What was the **severity** of your MOUTH OR THROAT SORES at their WORST?
  - None / Mild / Moderate / Severe / Very severe

- How much did MOUTH OR THROAT SORES **interfere** with your usual or daily activities?
  - Not at all / A little bit / Somewhat / Quite a bit / Very much
PRO-CTCAE Score vs. CTCAE Grade

• PRO-CTCAE responses are scored from 0 to 4
  • Up to three questions per AE Item
    • Frequency, Severity, Interference

• Clinician CTCAE Grade
  • Bundles the constructs of severity, frequency and interference
  • Grading dependent upon clinician judgement of medical significance

• Clinician Grade ≠ PRO-CTCAE Score
  • One grade by clinician
  • Up to three patient reported scores per Item
  • CTCAE Grade 4 does not exist for most of the PRO-CTCAE items
HRQOL ≠ Toxicity Reporting

**HRQOL**
- Questions designed to address overall effects of cancer and its treatment
- Patient answers questions in real time
- Responses evaluated by study at the completion of the study
- Tools are designed to provide a summary score

**Toxicity Reporting**
- Clinician assesses adverse events for patient safety
- Action is taken specifically to reducing further harm
- Events reviewed in real time and study design may be modified
- Each event is reported independently
Key Points

• Different tools used for different purposes

• HRQOL provides an assessment for multiple different domains on how a patient experiences the combination of cancer, its treatment and related effects.

• Toxicity reporting is specific to safety and patients may not be aware of what is treatment related or cancer related.
Key Points

• PRO-CTCAE is a new tool:
  - Derived from clinician rated CTCAE for the purpose of refining the understanding of adverse events as a consequence of treatment.

• Clinician graded CTCAE remains standard for protocol directed action specific individual adverse events

• PRO-CTCAE provides descriptive information to compliment clinician reporting

• Much more work is needed to understand how best to use PRO-CTCAE data.
Ongoing Work

• Responsiveness, minimal clinically important difference, cut-points, relationship among the attributes

• Several languages in development/validation, including Chinese, Korean, Italian, French, Swedish, Dutch, and Danish

• Evaluate different approaches to patient-investigator grade reconciliation and to analyzing and representing PRO-CTCAE data
NCI PRO-CTCAE Study Group

Supported through NCI contracts HHSN261200800043C and HHSN261201000063C

Organizational Affiliations: NCI Community Cancer Centers Program (NCCCP), RTOG, Alliance, FDA

We gratefully acknowledge our study participants and patient representatives!

Ethan Basch
Sandra Mitchell
Amy Abernethy
Jeff Abrams
Suneel Allareddy
Benjamin Arnold
Pamela Atherton
Thomas Atkinson
Natalie Barragan
Paul Baumgartner
Lauren Becker
Antonia Bennett
Nancy Breen
Deborah Bruner
Laurie Burke
Kate Castro
David Cella
Alice Chen
Ram Chilukuri
Steven Clauser
Charles Cleeland

Catherine Coleman
Stephanie Consoli
Cori Couture
Andrea Denicoff
Amylou Dueck
Jana Eisenstein
Maria Fawzy
Shanda Finnigan
Steve Friedman
Joshua Gagne
Vinay Gangoli
Marcha Gatewood
Araceli Garcia-Gonzalez
Cindy Geoghegan
Maria Gonzalez
Mehul Gulati
Gaurav Gupta
Jennifer Hay
Madeline Hernandez-Krause
Jessica Hess
Lori Hudson
Norval Johnson

Joseph Kelaghan
Reshma Koganti
Edward Korn
George Komatsoulis
Virginia Kwitkowski
Suzanne Lechner
Lauren Lent
Yuelin Li
Carol Lowenstein
Donna Malveaux
Michael Mejia
Tito Mendoza
Lori Minasian
Michael Montello
Hannah O'Gorman
Ann O'Mara
Diane Paul
John Payne
Frank Penedo
Barbara Perez
Richard Piekarz
Liora Pollick

Katherine Ramsey
Bryce Reeve
Lauren Rogak
Dave Rothfarb
Sean Ryan
Daniel Satele
Martin Schoen
Deborah Schrag
Ann Setser
Eve Shalley
Mary Shaw
Marwan Shouery
Laura Sit
Jeff Sloan
Diane St. Germain
Ann Marie Trentascosti
Ted Trimble
Andy Trotti
Andrea Vinard
Vish Viswanath
Gordon Willis
Jennifer Wind